An eye to the future: Researchers debate best path for stem cell-derived therapies
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The first in-human clinical trial of iPSC-based cell therapy used an iPSC-derived retinal pigment epithelium (RPE) sheet that was implanted into a Japanese woman with age-related macular degeneration (AMD) in 2014 [73,74].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [74]
In the citing paper
“This patient did not experience any complications during surgery or after the surgery, however, the patient was required to wait over 10 months for the surgery and it cost nearly USD 1 million [75].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [74]
Citations
Cites
Song, W. K., Park, K.-M., Kim, H.-J., Lee, J. H., Choi, J., Chong, S. Y., Shim, S. H., Del Priore, L. V., & Lanza, R. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.04.005 · Cited by 393
Cited by
Non-syndromic retinitis pigmentosa
Verbakel, S. K., van Huet, R. A. C., Boon, C. J. F., den Hollander, A. I., Collin, R. W. J., Klaver, C. C. W., Hoyng, C. B., Roepman, R., & Klevering, B. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.005 · Cited by 973
“Therefore, options for using human leukocyte antigen (HLA)-matched iPSCs from a databank are receiving increasing attention (Chakradhar, 2016; de Rham and Villard, 2014).”
Deuse, T., Hu, X., Gravina, A., Wang, D., Tediashvili, G., De, C., Thayer, W. O., Wahl, A., Garcia, J. V., Reichenspurner, H., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0016-3 · Cited by 758
Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications
Yoshihara, M., Hayashizaki, Y., & Murakawa, Y. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9680-6 · Cited by 283
“Even though there was no clear evidence that these mutations could directly lead to adverse effects, the planned transplantation surgery of iPSC-derived RPE sheet was cancelled [9, 10].”
BackgroundKirkeby, A., Nolbrant, S., Tiklova, K., Heuer, A., Kee, N., Cardoso, T., Ottosson, D. R., Lelos, M. J., Rifes, P., Dunnett, S. B., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2016.09.004 · Cited by 259
“As protocols to form authentic and functional cellular derivatives from hPSCs become increasingly refined, stem cell-based therapies are rapidly moving closer to clinical trials (Chakradhar, 2016).”
A new perspective on lipid research in age-related macular degeneration
van Leeuwen, E. M., Emri, E., Merle, B. M. J., Colijn, J. M., Kersten, E., Cougnard-Gregoire, A., Dammeier, S., Meester-Smoor, M., Pool, F. M., de Jong, E. K., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.04.006 · Cited by 247
“…iPSCs retain the epigenetic memory of their tissue of origin, and spontaneous genetic mutations may be introduced through the experimental process (Chakradhar, 2016; Hu et al., 2010; Kim et al., 2010; Polo et al., 2010), iPSC cells can produce extracellular lipid and lipoprotein deposits…”
BackgroundProtze, S. I., Lee, J. H., & Keller, G. M. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.07.010 · Cited by 162
Stem/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials
Wang, Y., Tang, Z., & Gu, P. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02955-3 · Cited by 111
Autologous Pluripotent Stem Cell–Derived β-Like Cells for Diabetes Cellular Therapy
Millman, J. R., & Pagliuca, F. W. (2017) · Diabetes · doi:10.2337/db16-1406 · Cited by 99
“However, a second patient has not yet been transplanted for a variety of reasons, including identification of a genomic mutation in the derived autologous hiPSCs (57).”
BackgroundRecent Advances in Age-Related Macular Degeneration Therapies
Fabre, M., Mateo, L., Lamaa, D., Baillif, S., Pagès, G., Demange, L., Ronco, C., & Benhida, R. (2022) · Molecules · doi:10.3390/molecules27165089 · Cited by 111
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“The first in-human clinical trial of iPSC-based cell therapy used an iPSC-derived retinal pigment epithelium (RPE) sheet that was implanted into a Japanese woman with age-related macular degeneration (AMD) in 2014 [73,74].”
Genomic Instability of iPSCs and Challenges in Their Clinical Applications
Yoshihara, M., Oguchi, A., & Murakawa, Y. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-31206-0_2 · Cited by 60
Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis
Pluchino, S., Smith, J. A., & Peruzzotti-Jametti, L. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.04.005 · Cited by 59
“For example, the cost of a single autologous iPSC treatment has been estimated at ~1 million US$ [86], but improvements in manufacturing scale and efficiency are likely to be met by a concomitant reduction in costs.”
BackgroundChallenges in the clinical advancement of cell therapies for Parkinson’s disease
Skidmore, S., & Barker, R. A. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00987-y · Cited by 59
“Inter-individual genetic variation is concordant with batch heterogeneity, necessitating reprogramming, adaptation of the differentiation culture protocol and the use of non-standardised progenitor cultures, many of which may need to be abandoned due to unsuitability 111–113 .”
BackgroundBerry, B. J., Smith, A. S. T., Young, J. E., & Mack, D. L. (2018) · Cells Tissues Organs · doi:10.1159/000493018 · Cited by 48
“In 2015, safety concerns prevented the progression of the first-in-human clinical trial of patient-derived stem cells [Chakradhar, 2016].”
BackgroundArroyave, F., Montaño, D., & Lizcano, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228685 · Cited by 63
“Therefore, most regenerative approaches that rely on the generation of autologous iPSCs have been abandoned [219,220].”
BackgroundEngineering-derived approaches for iPSC preparation, expansion, differentiation and applications
Li, Y., Li, L., Chen, Z., Gao, G., Yao, R., & Sun, W. (2017) · Biofabrication · doi:10.1088/1758-5090/aa7e9a · Cited by 45
Oh, S., Jang, A. Y., Chae, S., Choi, S., Moon, J., Kim, M., Spiekerkoetter, E. F., Zamanian, R. T., Yang, P. C.-M., Hwang, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81244-1 · Cited by 39
Induced pluripotent stem cell-based therapy for age-related macular degeneration
Bracha, P., Moore, N. A., & Ciulla, T. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1346079 · Cited by 42
“Of note, she did not receive immunosuppression [128], in”
BackgroundInfluentialFields, M. A., Cai, H., Gong, J., & Priore, L. V. D. (2016) · Cells · doi:10.3390/cells5040044 · Cited by 43
“Even though the first patient suffered “no serious adverse effects” of treatment, the trial has been put on hold due to the discovery of genetic mutations identified in the iPSCs that were to be used in a second patient in 2015 [94,95].”
BackgroundSalerno, N., Salerno, L., Marino, F., Scalise, M., Chiefalo, A., Panuccio, G., Angelis, A. D., Cianflone, E., Urbanek, K., & Torella, D. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101530 · Cited by 28
Making it personal: The prospects for autologous pluripotent stem cell-derived therapies
Blair, N. F., & Barker, R. A. (2016) · Regenerative Medicine · doi:10.2217/rme-2016-0057 · Cited by 22
Chen, Y., Zhou, Y., Zhou, Z., Fang, Y., Ma, L., Zhang, X., Xiong, J., & Liu, L. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03233-z · Cited by 22
Generation of Xeno‐Free, cGMP‐Compliant Patient‐Specific iPSCs from Skin Biopsy
Wiley, L. A., Anfinson, K. R., Cranston, C. M., Kaalberg, E. E., Collins, M. M., Mullins, R. F., Stone, E. M., & Tucker, B. A. (2017) · Current Protocols in Stem Cell Biology · doi:10.1002/cpsc.30 · Cited by 24
Cell Therapies For Parkinson'S Disease: How Far Have We Come?
Stoker, T. B., & Barker, R. A. (2016) · Regenerative Medicine · doi:10.2217/rme-2016-0102 · Cited by 23
The translational potential of human induced pluripotent stem cells for clinical neurology
Devine, H. E., & Patani, R. (2016) · Cell Biology and Toxicology · doi:10.1007/s10565-016-9372-7 · Cited by 19
“Excitingly, the first hiPSC trial into human patients with age-related macular degeneration took place in 2014 where autologous hiPSC-derived retinal pigment epithelial cells were implanted (Chakradhar 2016).”
BackgroundApplication of Cancer Cell Reprogramming Technology to Human Cancer Research
Pan, X.-Y., Tsai, M.-H., Wuputra, K., Ku, C., Lin, W., Lin, Y., Kishikawa, S., Noguchi, M., Saito, S., Lin, C., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11703 · Cited by 18
Tissue engineering in age-related macular degeneration: a mini-review
Wu, A., Lu, R., & Lee, E. (2022) · Journal of Biological Engineering · doi:10.1186/s13036-022-00291-y · Cited by 19
“iPSCs are developed by harvesting adult somatic cells from the patient’s own tissues [54].”
BackgroundCianflone, E., Scalise, M., Marino, F., Salerno, L., Salerno, N., Urbanek, K., & Torella, D. (2022) · Clinical Science · doi:10.1042/cs20220391 · Cited by 14
Todorova, D., Zhang, Y., Chen, Q., Liu, J., He, J.-J., Fu, X.-M., & Xu, Y. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103120 · Cited by 11
Li, L., Yu, Y. G., Lin, S., & Hu, J. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02931-y · Cited by 12
“In 2014, a 70-year-old Japanese woman with AMD became the first person in the world to receive treatment based on iPSCs [27].”
BackgroundHypoimmunogenic Human iPSCs for Repair and Regeneration in the CNS
Zhang, H., Zhou, H., Xia, X., Cao, Q., & Liu, Y. (2025) · Cells · doi:10.3390/cells14161248 · Cited by 13
Heyder, C., Hansen, S. L., & Wiesemann, C. (2020) · The New Bioethics · doi:10.1080/20502877.2020.1724708 · Cited by 7
“Because of considerable differences in quality, the hiPSC researcher Masayo Takahashi had to generate 30 cell lines in order to be able to choose the best ones for treating age-related macular degeneration in the first patient in the RIKEN trial (Chakradhar 2016).”
BackgroundEffect of Chinese Herbal Medicine on Molecular Imaging of Neurological Disorders
Yao, Y., Chen, T., Huang, J., Zhang, H., & Tian, M. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.02.009 · Cited by 7
Regenerative Medicine: Advances from Developmental to Degenerative Diseases
Blair, N. F., Frith, T. J. R., & Barbaric, I. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-60733-7_12 · Cited by 9
The Future of Brain Repair: A Realist's Guide to Stem Cell Therapy
Price, J. (2020) · The MIT Press eBooks · doi:10.7551/mitpress/10837.001.0001 · Cited by 4
Bioengineering of Human Corneal Endothelial Cells from Single- to Four-Dimensional Cultures
Tsao, Y.-T., Cheng, C.-M., Wu, W.-C., & Chen, H.-C. (2020) · Current Ophthalmology Reports · doi:10.1007/s40135-020-00244-y · Cited by 3
From genome editing to blastocyst complementation: A new horizon in heart transplantation?
Konstantinov, I. E., King, G., & Porrello, E. R. (2022) · JTCVS Techniques · doi:10.1016/j.xjtc.2022.01.012 · Cited by 4
“However, the cost per individual patient and the time required to generate sufficient cell quantities or develop grafts for transplantation is currently seen as a prohibitive factor in the utilization of autologous iPSCs.(16,17) This is particularly problematic for time-sensitive clinical indications, such as ischemic…”
BackgroundLee, J.-M., Lee, C., Seol, B., Jung, C. K., Kim, Y., Kang, D., Yu, H., Hong, Y., Song, C. L., Cho, Y. S., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01439-8 · Cited by 4
“This is a potential concern when using iMS cells for therapeutic applications 6 .”
Hu, X., Deuse, T., Gravina, A., Wang, D., Tediashvili, G., De, C., Thayer, W. O., Wahl, A. R., García, V. H. R., Reichenspurner, H. C., et al. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.01.749 · Cited by 2
Stammzellforschung: Aktuelle wissenschaftliche und gesellschaftliche Entwicklungen
Zenke, M., Marx-Stölting, L., Schickl, H., & Verlagsgesellschaft, N. (2018) · Nomos Verlagsgesellschaft mbH & Co. KG eBooks · doi:10.5771/9783845287720 · Cited by 7
Lee, J. S., Lee, J. E., Yu, S.-H., Chun, T., Chang, M., Lee, D. R., & Park, C. (2023) · International Journal of Stem Cells · doi:10.15283/ijsc23037 · Cited by 2
“Over the last few decades, hPSCs have been extensively used in cellular research due to their potential as renewable cell sources for drug toxicity screening, human cell therapy, and regenerative medicine (21-23).”
BackgroundLi, S., Zheng, Y., Xue, H., Zhang, H., Wu, J., Chen, X., Bouza, M. P., Yi, S., Zhou, H., Xia, X., et al. (2025) · Biology · doi:10.3390/biology14070791 · Cited by 2
Introduction and Basic Concepts in Stem Cell Research and Therapy: The Facts and the Hype
Essawy, M., Shouman, S., Magdy, S., Abdelfattah‐Hassan, A., & El‐Badri, N. (2020) · Learning materials in biosciences · doi:10.1007/978-3-030-55359-3_1 · Cited by 2
An update on clinical applications of iPSCs from a genomic point of view
Yoshihara, M., & Murakawa, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99892-5.00001-3 · Cited by 2
iPSC Technology Applying in Cell Therapy
Chuang, J.-H., & Chang, Y.-F. (2025) · Springer eBooks · doi:10.1007/978-981-96-1261-1_24 · Cited by 1
Yu, H. G. (2022) · Springer eBooks · doi:10.1007/978-981-16-7337-5_4 · Cited by 1
The therapeutic potential of exogenous adult stem cells for the injured central nervous system
Smith, J. A., Braga, A., Hamel, R., Rutigliani, C., Yu, B., Peruzzotti‐Jametti, L., & Pluchino, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00006-4 · Cited by 1
Signaling pathways regulate cardiovascular lineage commitment of hPSCs
Han, P., & Cho, H. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90059-1.00013-0
Generation of TNFαR1 and ASIC1a Knockout Human Neural Stem Cells In Vitro by CRISPR/Cas9 System
Poltavets, A. S., Mescheryakova, N. V., Kolesova, Y. S., Artyuhov, A., & Dashinimaev, E. B. (2021) · Neurochemical Journal · doi:10.1134/s1819712421040103
Update on stem/progenitor cell-based clinical trials for eye disease
El-Hashash, A. H. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99987-8.00003-5
Roles of Ipsc in Advancing Treatments for Neurological DisordersPreprint
Zhang, X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4818803
Research progress on chemical reprogramming for inducing human pluripotent stem cells
Cheng, L., & Deng, H. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0301
Li, L., Yu, Y., Lin, S., & Hu, J. (2022) · Figshare · doi:10.6084/m9.figshare.20023175
Chen, Y., Zhou, Y., Zhou, Z., Fang, Y., Ma, L., Zhang, X., Xiong, J., & Liu, L. (2023) · Figshare · doi:10.6084/m9.figshare.22609745
Metadata
- Authors
- Chakradhar, S.
- Corresponding author
- Chakradhar, Shraddha
- Venue
- Nature Medicine
- Published
- 2016-02
- Volume
- 22
- Issue
- 2
- Pages
- 116-119
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2266236998
- Cited by
- 56
- References
- 1
- Citations by year
- 2025: 5 · 2024: 1 · 2023: 5 · 2022: 10 · 2021: 3 · 2020: 10 · 2019: 3 · 2018: 5 · 2017: 8 · 2016: 6
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- stem cell transplantation, age-related macular degeneration, dry age-related macular degeneration, visual acuity, tissue engineering, mesenchymal stem cells, pulmonary arterial hypertension, anti-inflammatory activity, immunomodulation
- MeSH terms
- Human Embryonic Stem Cells, Costs and Cost Analysis, Humans, Macular Degeneration, Mutation, Transplantation, Autologous, Transplantation, Homologous, Stem Cell Transplantation, Biomedical Research, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.